pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,162 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT954Endpoints732BioPharma Dive280BioSpace177Fierce Biotech167onclive165globenewswire health73raps
therapy area
allOncology5569Rare Disease1219Cardiology1039Hematology916Immunology907Vaccines793Pulmonology
  • Aardvark Therapeutics abandons phase 3 trials after workforce cuts and FDA hold
    Aardvark Therapeutics announced it is walking away from its recently terminated phase 3 trials, stating there are no plans to resume them as originally designed. The decision follows a reduction i…
    Fierce Biotech · 1d agoRegulatoryNegative↗ source
  • Samsung gets FDA clearance for Galaxy Buds hearing-aid features
    Samsung Electronics received FDA clearance for new software features in its Galaxy Buds earphones that let them function as over-the-counter hearing aids and conduct hearing tests. The hearing tes…
    Fierce Biotech · 1d agoApprovalPositive↗ source
← prev
page 3 of 87
next →
59
fda recalls39
fda medwatch29
fda press25
768
Psychiatry & CNS677
Ophthalmology338
Endocrinology & Metabolism335
Pain328
Infectious Disease320
  • AI-focused biotech firms drive biopharma toward a 'fail-fast' drug development model
    AI is quickly becoming a central force in drug development as tech capital pours into biopharma, reshaping how new medicines are discovered. Tyrone Lam, chief business officer at GATC Health, says…
    BioSpace · 1d agoPositive↗ source
  • White House rolls out treatment-first addiction toolkit emphasizing faith-based care and abstinence
    The Trump administration introduced a new framework for addressing addiction and homelessness, called a "treatment-first" toolkit. The toolkit prioritizes medical treatment and faith-based program…
    STAT · 1d agoRegulatoryNeutral↗ source
  • Eli Lilly sues six U.S. firms over alleged black-market sales of investigational drug retatrutide
    Eli Lilly has filed lawsuits against six U.S. companies it says are selling its investigational diabetes and weight-loss drug retatrutide. The companies are accused of operating a black-market for…
    Endpoints · 1d agoNegative↗ source
  • BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026
    BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…
    BioSpace · 1d agoNeutral↗ source
  • Commure's AI-driven referral program draws complaints of financial losses from health-care customers
    Commure, a Silicon Valley startup valued at $7 billion, builds AI tools aimed at automating health‑care administrative work such as scheduling, billing and prior‑authorization. According to intern…
    STAT · 1d agoNegative↗ source
  • Climate change worsens symptoms for people with chronic illnesses, author reports from Chicago smoke events
    The author argues that climate change is already harming health, particularly for those living with chronic conditions, and that the impact is becoming more evident. She describes a recent summer…
    STAT · 1d agoNegative↗ source
  • FDA releases proposed commitment letter detailing changes to GDUFA IV program
    The U.S. Food and Drug Administration has issued a proposed commitment letter for the fourth reauthorization of the Generic Drug User Fee Amendments (GDUFA IV). The letter follows several months o…
    raps · 1d agoRegulatoryNeutral↗ source
  • Vaping and cannabis use hit record highs among U.S. young adults in 2025, survey finds
    A new national survey by the University of Michigan shows vaping and cannabis use among U.S. young adults reached record levels in 2025. Past‑30‑day nicotine vape use rose to 19%, more than triple…
    STAT · 1d agoNegative↗ source
  • Vaccine makers say splitting MMR vaccine is impractical despite presidential directive
    Vaccine manufacturers responded to a recent order from President Donald Trump to separate the combined measles, mumps and rubella (MMR) vaccine, noting that while the concept is theoretically possi…
    Endpoints · 1d agoNeutral↗ source
  • Postpartum psychiatry remains inadequately understood, case of Lindsay Clancy highlights gaps
    The opinion piece, authored by a neuroscience professor at Tufts, an obstetrics‑psychiatry specialist at NewYork‑Presbyterian and Weill Cornell, and a psychiatry researcher at the University of Vir…
    STAT · 1d agoNegative↗ source
  • North Carolina biopharma job postings jump 26% as seven companies announce dozens of openings
    Bio NC’s hotbed is seeing a surge in employment opportunities, with BioSpace data showing a 26% year‑over‑year rise in job postings in July and an upward trend since November. Seven companies are…
    BioSpace · 1d agoPositive↗ source
  • Renowned autoimmune researcher Georg Schett co-founds biotech to develop antibody therapies
    Georg Schett, a German scientist noted for pioneering CAR‑T approaches in autoimmune disease, is now launching a new biotech venture. The startup, which has not yet been named in the report, will…
    STAT · 1d agoDealPositive↗ source
  • Endpoints News recaps Boston China biotech debate on industry’s China outlook
    Last week Endpoints News hosted a live debate in Boston that brought together leading voices in biopharma to discuss China’s growing role in the industry. The panel featured executives and investo…
    Endpoints · 1d agoNeutral↗ source
  • Inside a Secret AI Startup: Challenges of Building and Selling Clinical Tools
    The STAT+ newsletter reveals that a health‑tech reporter has been quietly developing an artificial‑intelligence startup for the past six months. The piece describes the difficulties of rapidly cre…
    STAT · 1d agoNeutral↗ source
  • Missed promotion often reflects organizational timing, not personal failure
    A missed promotion can feel like a verdict on one’s potential, yet the source notes that employees and organizations often develop at different speeds. Executive coach Angela Justice recounts a ca…
    BioSpace · 1d agoNeutral↗ source
  • Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
    Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.
    Fierce Biotech · 1d ago↗ source
  • Definium's LSD-based therapy shows strong Phase 3 results in generalized anxiety disorder
    Definium Therapeutics reported that its LSD-derived oral tablet, DT120, met its primary endpoint in a Phase 3 trial for generalized anxiety disorder. The study enrolled over 200 participants and co…
    Fierce Biotech · 2d agoPositive readoutPositive↗ source
  • Eli Lilly fronts $2 billion for vaccine biotech deals as Infinimmune secures $75 million funding
    Eli Lilly announced it has paid $2 billion up front as part of its ongoing strategy to acquire vaccine‑focused biotechnology companies, a portion of a larger deal that could total up to $3.8 billio…
    Endpoints · 2d agoDealPositive↗ source
  • Medicaid to End Funding for Gender-Affirming Surgeries and Hormone Therapy for Transgender Youth
    The Trump administration announced that Medicaid will no longer cover gender-affirming surgeries and hormone treatments for minors. The change also applies to the Children’s Health Insurance Progr…
    STAT · 1d agoRegulatoryNegative↗ source
  • Combination therapy including leronlimab clears HIV in infant macaques, offering new cure hope
    CytoDyn researchers tested leronlimab together with broadly neutralizing antibodies and antiretroviral therapy in a cohort of 55 infant macaques. Only the eight animals that received the full three…
    Fierce Biotech · 2d agoPositive readoutPositive↗ source
  • Health industry pushes back against Trump’s vaccine executive order
    President Trump signed an executive order this week that would overhaul the federal childhood‑vaccination program, calling for fewer shots administered over a longer period. The order specifically…
    STAT · 2d agoRegulatoryNegative↗ source
  • Insilico Medicine CEO touts billions in pipeline deals at BIO International Convention
    At the BIO International Convention in June, Insilico Medicine chief Alex Zhavoronkov made a high‑energy appearance that attracted considerable attention. Zhavoronkov handed out a postcard‑sized l…
    BioSpace · 2d agoDealPositive↗ source
  • Epicrispr and Infinimmune secure $165 million in venture funding for epigenetic and antibody programs
    Epicrispr Biotechnologies announced a $90 million Series C round to push its epigenetic therapy program for facioscapulohumeral muscular dystrophy (FSHD). The lead candidate, EPI-321, is in a firs…
    BioSpace · 2d agoDealPositive↗ source